Legal & General Group Plc Purchases Shares of 39,893 AtriCure, Inc. $ATRC

Legal & General Group Plc bought a new stake in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 39,893 shares of the medical device company's stock, valued at approximately $1,116,000. Legal & General Group Plc owned about 0.08% of AtriCure at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. AQR Capital Management LLC boosted its stake in AtriCure by 1.0% in the first quarter. AQR Capital Management LLC now owns 83,685 shares of the medical device company's stock worth $2,700,000 after buying an additional 837 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of AtriCure by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,146 shares of the medical device company's stock worth $908,000 after acquiring an additional 1,230 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of AtriCure by 1.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 862,668 shares of the medical device company's stock valued at $27,830,000 after purchasing an additional 8,956 shares in the last quarter. Jane Street Group LLC boosted its stake in shares of AtriCure by 658.3% in the 1st quarter. Jane Street Group LLC now owns 100,853 shares of the medical device company's stock valued at $3,254,000 after purchasing an additional 87,553 shares in the last quarter. Finally, Strs Ohio bought a new position in shares of AtriCure during the 1st quarter valued at $158,000. Hedge funds and other institutional investors own 99.11% of the company's stock.

AtriCure Stock Performance

Shares of ATRC opened at $51.52 on Tuesday. AtriCure, Inc. has a 12 month low of $25.36 and a 12 month high of $53.50. The business's fifty day simple moving average is $40.56 and its two-hundred day simple moving average is $32.96. The company has a market cap of $2.62 billion, a price-to-earnings ratio of 245.35 and a beta of 1.26. The company has a current ratio of 4.22, a quick ratio of 3.19 and a debt-to-equity ratio of 0.14.

AtriCure (NASDAQ:ATRC - Get Free Report) last issued its earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.The business had revenue of $153.60 million during the quarter, compared to analyst estimates of $151.80 million. During the same quarter in the previous year, the firm earned ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Research analysts anticipate that AtriCure, Inc. will post 0.29 earnings per share for the current fiscal year.

Insider Activity at AtriCure

In other AtriCure news, insider Justin Noznesky sold 6,182 shares of the stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $38.80, for a total value of $239,861.60. Following the transaction, the insider owned 100,219 shares of the company's stock, valued at approximately $3,888,497.20. This represents a 5.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Karen Prange sold 3,564 shares of the stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $38.80, for a total transaction of $138,283.20. Following the completion of the transaction, the director owned 22,809 shares in the company, valued at $884,989.20. This trade represents a 13.51% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 61,379 shares of company stock valued at $2,557,552 in the last 90 days. 4.00% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

ATRC has been the topic of several analyst reports. Needham & Company LLC lifted their price objective on AtriCure from $45.00 to $64.00 and gave the stock a "buy" rating in a report on Wednesday, September 2nd. Weiss Ratings upgraded AtriCure from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Wednesday, August 19th. Raymond James Financial set a $52.00 price target on AtriCure in a research note on Tuesday, July 21st. BTIG Research boosted their price objective on AtriCure from $45.00 to $55.00 and gave the company a "buy" rating in a research report on Monday, August 24th. Finally, UBS Group dropped their price objective on AtriCure from $55.00 to $50.00 and set a "buy" rating for the company in a research note on Tuesday, July 28th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $52.00.

AtriCure Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company's solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company's product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.

Want to see what other hedge funds are holding ATRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AtriCure, Inc. (NASDAQ:ATRC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.